Drug Profile
KW 3
Alternative Names: KW-3Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Beijing Kawin Technology Share-Holding
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Liver cancer; Malignant melanoma
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Liver cancer in China (Parenteral) before September 2023 (Beijing Kawin Technology Share-Holding pipeline, September 2023)
- 05 Sep 2023 Discontinued - Preclinical for Malignant melanoma in China (Parenteral) before September 2023 (Beijing Kawin Technology Share-Holding pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Liver-cancer in China (Parenteral)